Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells. - Archive ouverte HAL Access content directly
Journal Articles Clinical and Experimental Allergy Year : 2016

Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells.

(1, 2) , (2) , (3) , (2, 3) , (2, 1) , (1, 4) , (3) , (2)
1
2
3
4

Abstract

Allergic asthma is an inflammatory disease of the airways, resulting from an inappropriate immune response to inhaled allergens, which involves multiple inflammatory cells and mediators that contribute to airway hyper-responsiveness. Omalizumab is a monoclonal antibody, specifically directed to the C-Epsilon3 domain of immunoglobulin E (IgE), indicated as an additional therapy in severe allergic asthma [1]. Impaired function of regulatory T cells (Treg) is incriminated in the aberrant asthma inflammatory response [2].

Dates and versions

inserm-01404099 , version 1 (28-11-2016)

Identifiers

Cite

Flore Amat, Pauline Tallon, Anne Perrine Foray, Bénédicte Michaud, Nathalie Lambert, et al.. Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells.. Clinical and Experimental Allergy, 2016, Epub ahead of print. ⟨10.1111/cea.12839⟩. ⟨inserm-01404099⟩
124 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More